NVCR outlook set for double-digit growth on launches, payer gains
Optune Pax’s stage III pancreatic cancer launch exceeded expectations with a 70% prescription-to-active patient conversion and early payer coverage. NVCR also cites Europe and Japan expansion, new clinical trials, and disciplined financial management.
Optune Pax's launch for stage III pancreatic cancer exceeded expectations, with a 70% prescription-to-active patient conversion and early payer coverage. The company said expansion in Europe and Japan, new clinical trials, and disciplined financial management leave it positioned for double-digit growth and profita…